Efficacy of single administration of oral NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving adjuvant AC-based chemotherapy – Results from GIM15-NEPA Study
Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabino De Placido, Vincenzo Montesarchio(CTO Hospital), Giovanni Scambia(Agostino Gemelli University Polyclinic), Valentina Guarneri(Istituto Oncologico Veneto), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Giuseppina Cilenti(Casa Sollievo della Sofferenza), Alessandra Fabi(Agostino Gemelli University Polyclinic), Serafino Ricci(Sapienza University of Rome), S. Molica, Ryan Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M. Giordano, Alessandra Cassano, Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Armando Santoro(IRCCS Humanitas Research Hospital), E. Bonizzoni, S. Fava, Alessio Schirone, Mario Nicolini(Azienda Ospedaliera Carlo Poma), Laura Amaducci(Ospedale degli Infermi)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830